Biopharmaceutical company Catabasis Pharmaceuticals has announced the promotion of Noah Clauser to Chief Financial Officer. Mr. Clauser will oversee all of the company’s financial operations, and report to Chief Executive Officer Jill C. Milne.
“Noah has strategically built our financial and operations functions and has been a valuable team member through a critical stage for Catabasis,” said Ms. Milne. “We are looking forward to his expanded role as we approach our potential future transition to a commercial organization.”
Mr. Clauser has been with Catabasis for nine years, including the last three years as Vice President, Finance. He has nearly 20 years of financial experience, and served as an Accounting Manager at Impress Software before joining Catabasis.
“I am excited for this new opportunity as we approach the next stage of our company, with top-line results from the Phase 3 PolarisDMD trial for edasalonexent expected in the fourth quarter of this year,” said Mr. Clauser. “I am looking forward to continuing our work to make an impact in the lives of patients and families affected by Duchenne muscular dystrophy.”